US 11,926,635 B2
P38α mitogen-activated protein kinase inhibitors
Adam Galan, Alameda, CA (US); Wendy Luo, Sunnyvale, CA (US); and Ritu Lal, Palo Alto, CA (US)
Assigned to GEN1E LIFESCIENCES INC., Palo Alto, CA (US)
Filed by GEN1E LIFESCIENCES INC., Palo Alto, CA (US)
Filed on Jul. 19, 2022, as Appl. No. 17/813,382.
Application 17/813,382 is a continuation of application No. 17/667,898, filed on Feb. 9, 2022, granted, now 11,440,918.
Application 17/667,898 is a continuation of application No. 17/320,874, filed on May 14, 2021, granted, now 11,286,260, issued on Mar. 29, 2022.
Claims priority of provisional application 63/026,466, filed on May 18, 2020.
Prior Publication US 2023/0090562 A1, Mar. 23, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 491/107 (2006.01); A61P 31/14 (2006.01); C07D 207/12 (2006.01); C07D 211/42 (2006.01); C07D 211/46 (2006.01); C07D 239/30 (2006.01); C07D 241/08 (2006.01); C07D 265/30 (2006.01); C07D 267/10 (2006.01); C07D 491/048 (2006.01); C07D 498/18 (2006.01)
CPC C07D 491/107 (2013.01) [A61P 31/14 (2018.01); C07D 207/12 (2013.01); C07D 211/42 (2013.01); C07D 211/46 (2013.01); C07D 239/30 (2013.01); C07D 241/08 (2013.01); C07D 265/30 (2013.01); C07D 267/10 (2013.01); C07D 491/048 (2013.01); C07D 498/18 (2013.01)] 35 Claims
 
1. A compound having the structure of Formula (1):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein,
R1 is selected from C1-4 alkanediyl, C1-4 heteroalkanediyl, substituted C1-4 alkanediyl, and substituted C1-4 heteroalkanediyl; and
R2 is a moiety having the structure of Formula (2d):

OG Complex Work Unit Chemistry
wherein,
each n is independently selected from, 1, 2, 3, and 4;
each A1 and A2 is independently selected from —CH2—, —CH(—R5)—, and —C(═O)—, wherein, each R5 is independently selected from —OH, —NH2, —NO2, C1-6 alkyl, C1-6 cycloalkyl, C6 aryl, C1-6 heteroalkyl, C1-6 heterocycloalkyl, C5-6 heteroaryl, substituted C1-6 alkyl, substituted C1-6 cycloalkyl, substituted C6 aryl, substituted C1-6 heteroalkyl, substituted C1-6 heterocycloalkyl, and substituted C5-6 heteroaryl;
one or more of A1 and A2 is independently selected from —CH(—R5)— and —C(═O)—; and
X is selected from CH(—OH)— and —SO2—.